TWI224003B - Stable mitoxantrone solutions - Google Patents
Stable mitoxantrone solutions Download PDFInfo
- Publication number
- TWI224003B TWI224003B TW088106569A TW88106569A TWI224003B TW I224003 B TWI224003 B TW I224003B TW 088106569 A TW088106569 A TW 088106569A TW 88106569 A TW88106569 A TW 88106569A TW I224003 B TWI224003 B TW I224003B
- Authority
- TW
- Taiwan
- Prior art keywords
- solution
- sodium
- ethylenediamine tetraacetate
- patent application
- scope
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
1224003 A7 B7 五、發明説明 技術領龙^ 本發明係有關於安定之米托森松溶液,其除了含有活 性成分米托森松(1 ’ 4 一二經基一 5,8 -二〔〔2 — 〔(2〜羥乙基)胺基〕乙基〕胺基〕蒽醌鹽酸鹽)外, 還含有安定劑,且不含有亞硫酸鹽化合物,以及有關於這 些溶液之注射用途與作爲注射液濃體(concentrate)之用 途。 先前技藝 米托森松爲蒽醌衍生物,化學名爲1,4 —二羥基-5 ’ 8 一二〔〔2 —〔 (2 -羥乙基)胺基〕乙基〕胺基 〕蒽醌鹽酸鹽,如下式所示, ho 〇 nhch2ch2nhch2ch2〇h
•2HCI HO 〇 nhch2ch2nhch2ch2〇h (請先閱讀背面之注意事項再填寫本頁) 、11 線 經濟部智慧財產局員工消費合作社印製 實驗式·· C 2 2 Η 2 8 N 4〇6 H C 1 米托森松具有抗贅瘤,抗病毒,抗原蟲,與免疫調節 等性質。此化合物特別有用於作爲細胞靜止素(c y t 〇 s t s t i c ),特別是用於治療乳癌,惡性淋巴瘤,急性血癌,初期 肝細胞癌,以及卵巢癌。 此化合物之水溶液已有作爲醫藥組成物。但是米托森 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -4- 1224003 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明説明) 松在水溶液中的安定性受到限制。若未採取措施減緩或·防 止此化合物的降解,其將進行氧化分解。特別是金屬離子 ,即使是極低濃度,將會增強此傾向。 已知此降解可藉由抗氧化劑來對抗。 ♦ EP — B — 0 2 3 6 8 22揭示一種製劑,係由抗氧 化劑,特定P Η値之偏亞硫酸氫鈉,與螯合劑(乙二胺四 乙酸二鈉)及甘胺酸之組合予以安定化。 雖然此組成物爲安、定的,但由於添加劑的副作用,仍 不令人完全滿意。其缺點在於使用偏亞硫酸氫鈉,此物質 爲非常有效之安定劑。 所以,加有亞硫酸鹽之米托森松溶液爲市售可得。當 使用含一般濃度亞硫酸鹽之製劑時,據報導曾有人發生嚴 重之過敏副作用。氣喘患者且對亞硫酸鹽過敏者,據報導 曾有人發生致命的倂發症。 此外,使用金屬離子與至少二種螯合劑之組合亦使組 成物中有額外的成分。 強酸性,即Ρ Η小於3,對耐受性與安定性亦爲缺點 (WANG, Da-Peng; LIANG, Gow-Zaw; TU, Yu-Hsing; Stability of mitoxantrone hydrochloride in solution, Drug Development and Industrial Pharmacy, 20(11),1 895 - 1 903 (1994))。 本發明目的在於避免副作用,且製成不含亞硫酸鹽之 水性製劑,其在一般貯存條件及3 0 ° C高溫有較長安定期 !·----- (請先閲讀背面之注意事項再填寫本頁) 訂 線· 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -5- 1224003 經濟部智慧財產局員工消費合作社印製 A7 _B7_五、發明説明(3 ) 發明說明 不同於前述專利EP — B — 0 2 3 6 8 22,本案出 人意料外地發現即使是乙二胺四乙酸鈉本身便足以使米托 ‘森松在水溶液中安定。 本發明係如下達成此目的:一種水性製劑,由1至5 mg米托森松鹽酸鹽/mL溶液,0·001至0·15 %乙二胺四乙酸鈉,以及氯化鈉,乙酸鈉,與乙酸所組成 。其pH値在3·0至4·5範圍內。 較好乙二胺四乙酸鈉的含量爲0 . 0 4 %。 本發明醫藥組成物可作爲治療前述癌症之注射液與注 射液濃體。其避免了所述副作用,且具有醫藥組成物所需 貯存安定性。 實施本發明的方法 製備本案溶液時,先將氯化鈉,乙酸鈉,乙酸與乙二 胺四乙酸鈉加至低氧水(1 〇 w - ο X y g e n w a t e r )中,然後溶解 。將米托森松鹽酸鹽加入一部份之此溶液中,然後溶解。 將此活性化合物之溶液與輔助劑加至其他部份之溶液中, 加入低氧水達最終體積。過濾所得溶液,分裝至注射瓶中 ,密封並封裝。 滅菌時使用一般防菌濾器,如,孔徑爲〇 . 2 μ m之濾 膜。所用容器事先以一般方法滅菌。所用的水必定要滅菌 ,且不可含熱源,即相當於European Pharmacopoeia 1997的 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ (請先閲讀背面之注意事項再填寫本頁) %ί. 訂 線 1224003 A7 !----B7________ 五、發明説明) 四乙酸鈉加至水中,然後溶解。水中的含氧量事先以適·宜 | 方式降低。將此溶液分成兩部分,將米托森松鹽酸鹽溶於 I 一部份之此溶液中。將含米托森松之溶液與剩餘之溶液混 I 合,加入低氧水達最終體積。 以濾膜過濾所得溶液而滅菌。 實例2 注射瓶中含1 2 · 5 m L 0 · 2 %濃度的米托森松 溶液。 米托森松溶液之組成與製備係如實例1 一般。 —Li------P, (請先閱讀背面之注意事項再填寫本頁)
丁 -V 安定性測試結果 張 紙 _本 經濟部智慧財產局員工消費合作社印製 組成 貯存 溫度 (°C) 雜質總3 Ώ (%)_ 起始 値 6個月 後 18個 月後 24個 月徐 實例2 25 0.60 0.75 0.72 __ 1.39 2.3 如實例2,但沒有乙 二胺四乙酸鈉 25 0.52 0.57 〜 1.73 實例2 30 0.60 0.82 1.78 2.00 如實例2,但沒有乙 二胺四乙酸鈉 30 0.52 0.93 2.74 4 1 f\ 實例2 40 0.60 1.45 1 · 1 VJ 如實例2,但沒有乙 二胺四乙酸鈉 40 0.52 2.72 —-— 尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 線 -8 -
Claims (1)
1224003
公 第8 8 1 〇 6 5 6 9號專利申請案 中文申請專利範圍替換本 民國93年7月26日修正 經濟部智慧財產局員工消費合作社印製 1 ·〜種安定之米托森松(mit〇xantrone)溶液,含 有1至5mg/mL溶液之米托森松鹽酸鹽,〇 · 〇〇;[ 至〇 · 1 5 %乙二胺四乙酸鈉,以及作爲額外成分之氯化 納’乙酸鈉,與乙酸,其中此溶液不含作爲安定劑之亞硫 酸鹽化合物。 2 ·如申請專利範圍第1項之溶液,係作爲注射液, 且乙二胺四乙酸鈉的含量爲0 · 0 4%。 3 .如申請專利範圍第1項之溶液,其中含有 0 ·004%乙二胺四乙酸二鈉。 4 · 一種製備如申請專利範圍第1至3項中任一項之 溶.液的方法,其特徵在於將氯化鈉,乙酸鈉,乙酸與乙二 月女四乙酸鈉溶於低氧水中,將米托森松鹽酸鹽加入一部份 之此溶液中,再與其他部份之此溶液混合,接著將最終體 積調整爲使米托森松鹽酸鹽的含量爲1至5 m g /m L溶 液,乙二胺四乙酸鈉的含量爲〇.001至〇.15%。 5 如申請專利範圍第4項的方法,其中加入 0 4 %乙二胺四乙酸鈉。 6 ·如申請專利範圍第4項之方法,其中加入 0 0 4%乙二胺四乙酸二鈉。 0 〇 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 、1T 1224003 A8 B8 C8 D8 六、申請專利範圍 7 . —種用於治療癌症之醫藥組成物,包括1至5 mg米托森松鹽酸鹽/mL溶液,〇·〇〇1至〇.15 %乙二胺四乙酸鈉(以米托森松鹽酸鹽溶液計),以及作 爲額外成分之氯化鈉,乙酸鈉,與乙酸,其中此組成物不 含作爲安定劑之亞硫酸鹽化合物。 8 .如申請專利範圍第7項之醫藥組成物,其中含有 〇 · 0 4 %乙二胺四乙酸鈉。 9 .如申請專利範圍第7項之醫藥組成物,其中含 有〇 · 0 0 4 %乙二胺四乙酸二鈉。 ---------βΐΗ-- (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19818802A DE19818802A1 (de) | 1998-04-27 | 1998-04-27 | Stabile Mitoxantron-Lösungen |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI224003B true TWI224003B (en) | 2004-11-21 |
Family
ID=7865948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088106569A TWI224003B (en) | 1998-04-27 | 1999-04-23 | Stable mitoxantrone solutions |
Country Status (18)
Country | Link |
---|---|
US (1) | US6143795A (zh) |
EP (1) | EP1073469B1 (zh) |
JP (1) | JP2002512981A (zh) |
CN (1) | CN1195548C (zh) |
AR (1) | AR018198A1 (zh) |
AT (1) | ATE282431T1 (zh) |
AU (1) | AU744502B2 (zh) |
BG (1) | BG64767B1 (zh) |
BR (1) | BR9909981A (zh) |
CA (1) | CA2270004C (zh) |
CO (1) | CO5021217A1 (zh) |
DE (2) | DE19818802A1 (zh) |
HK (1) | HK1036012A1 (zh) |
HU (1) | HUP0102075A3 (zh) |
NZ (1) | NZ507407A (zh) |
RU (1) | RU2219917C2 (zh) |
TW (1) | TWI224003B (zh) |
WO (1) | WO1999055375A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0005703D0 (en) * | 2000-03-09 | 2000-05-03 | Alpharma As | Compounds |
EP1615646B2 (en) | 2003-04-08 | 2022-07-27 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
CN102397561B (zh) * | 2011-09-26 | 2013-03-06 | 沈阳药科大学 | 米托蒽醌作为淋巴示踪剂的应用 |
JP5589110B1 (ja) * | 2013-03-08 | 2014-09-10 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
CN107149592B (zh) * | 2017-06-23 | 2019-10-08 | 沈阳天邦药业有限公司 | 具有淋巴靶向功能的生物自组装纳米晶注射剂及制备方法 |
CN113730603B (zh) * | 2020-05-27 | 2023-01-24 | 深圳华润九创医药有限公司 | 米托蒽醌制剂在制备诊治与甲状腺切除相关的疾病的药物中的应用 |
CN114601791B (zh) * | 2020-12-08 | 2023-09-19 | 成都倍特药业股份有限公司 | 一种盐酸米托蒽醌液体制剂及其制备方法 |
CN114732807A (zh) * | 2022-03-27 | 2022-07-12 | 苏州大学 | 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3248291A (en) * | 1963-08-19 | 1966-04-26 | Hoffmann La Roche | Stabilized thioxanthene derivatives and method of using the same |
ES2033247T3 (es) * | 1986-03-07 | 1993-03-16 | American Cyanamid Company | Metodo para preparar una composicion farmaceutica a base de un compuesto antraquinonico. |
IL83086A (en) * | 1987-07-06 | 1991-03-10 | Teva Pharma | Stable,injectable solutions of vincristine salts |
DE3825374A1 (de) * | 1988-07-26 | 1990-02-01 | Schwendener Reto Dipl Apotheke | Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren |
WO1994013274A1 (en) * | 1992-12-10 | 1994-06-23 | Abbott Laboratories | Stabilized catecholamine solutions |
FR2758264B1 (fr) * | 1997-01-16 | 1999-03-26 | Charles Dumontet | Compositions medicamenteuses contenant de l'edta ou un de ses derives pour la prevention de la toxicite cutanee et sous-cutanee des anthracyclines et de leurs derives |
-
1998
- 1998-04-27 DE DE19818802A patent/DE19818802A1/de not_active Ceased
-
1999
- 1999-04-01 JP JP2000545572A patent/JP2002512981A/ja active Pending
- 1999-04-01 BR BR9909981-0A patent/BR9909981A/pt not_active Application Discontinuation
- 1999-04-01 AT AT99916906T patent/ATE282431T1/de not_active IP Right Cessation
- 1999-04-01 NZ NZ507407A patent/NZ507407A/xx unknown
- 1999-04-01 HU HU0102075A patent/HUP0102075A3/hu unknown
- 1999-04-01 CN CNB998055794A patent/CN1195548C/zh not_active Expired - Fee Related
- 1999-04-01 RU RU2000129666/14A patent/RU2219917C2/ru active
- 1999-04-01 WO PCT/EP1999/002290 patent/WO1999055375A1/de active IP Right Grant
- 1999-04-01 DE DE59911099T patent/DE59911099D1/de not_active Expired - Fee Related
- 1999-04-01 AU AU35225/99A patent/AU744502B2/en not_active Ceased
- 1999-04-01 EP EP99916906A patent/EP1073469B1/de not_active Expired - Lifetime
- 1999-04-07 CO CO99020294A patent/CO5021217A1/es unknown
- 1999-04-23 TW TW088106569A patent/TWI224003B/zh not_active IP Right Cessation
- 1999-04-26 CA CA002270004A patent/CA2270004C/en not_active Expired - Fee Related
- 1999-04-26 US US09/299,131 patent/US6143795A/en not_active Expired - Fee Related
- 1999-04-27 AR ARP990101932A patent/AR018198A1/es unknown
-
2000
- 2000-10-12 BG BG104850A patent/BG64767B1/bg unknown
-
2001
- 2001-09-24 HK HK01106731A patent/HK1036012A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2270004A1 (en) | 1999-10-27 |
WO1999055375A1 (de) | 1999-11-04 |
AU3522599A (en) | 1999-11-16 |
HUP0102075A2 (hu) | 2002-05-29 |
JP2002512981A (ja) | 2002-05-08 |
AR018198A1 (es) | 2001-10-31 |
RU2219917C2 (ru) | 2003-12-27 |
CN1298310A (zh) | 2001-06-06 |
CN1195548C (zh) | 2005-04-06 |
NZ507407A (en) | 2002-08-28 |
CA2270004C (en) | 2004-06-01 |
AU744502B2 (en) | 2002-02-28 |
EP1073469B1 (de) | 2004-11-17 |
HK1036012A1 (en) | 2001-12-21 |
BR9909981A (pt) | 2000-12-26 |
CO5021217A1 (es) | 2001-03-27 |
BG64767B1 (bg) | 2006-03-31 |
US6143795A (en) | 2000-11-07 |
DE19818802A1 (de) | 1999-10-28 |
DE59911099D1 (de) | 2004-12-23 |
BG104850A (en) | 2001-05-31 |
ATE282431T1 (de) | 2004-12-15 |
EP1073469A1 (de) | 2001-02-07 |
HUP0102075A3 (en) | 2002-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0185377B1 (ko) | 정신작용성 약물의 안정화된 용액 | |
AU771058B2 (en) | Moxifloxacin formulation containing common salt | |
EP2307056B1 (en) | Stabilized aqueous formulation containing paracetamol | |
CN106061467B (zh) | 用于产生去甲肾上腺素的稳定低浓度、可注射溶液的方法 | |
TWI224003B (en) | Stable mitoxantrone solutions | |
TWI277414B (en) | Esmolol formulation | |
US4822823A (en) | Aqueous preparation and method of preparation thereof | |
US20070155768A1 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
KR100188318B1 (ko) | 안정화된 주사제 및 주사제의 안정화법 | |
NZ522329A (en) | Novel formulations of -2,4-disulfophenyl-N-tert-butylnitrone | |
JP3949184B2 (ja) | 塩酸アンブロキソール水性液剤 | |
JPH01259850A (ja) | Mn(II)配位組成物を使用するNMR像形成 | |
MXPA03002770A (es) | Infusion de ciprofloxacina con un contenido de acido reducido y estable al almacenamiento. | |
EP0236822B1 (en) | Stable injectable pharmaceutical formulation for 1,4-dihydroxy-5,8-bis((2-(hydroxyethylamino)-ethyl)amino)anthraquinone, dihydrochloride | |
GB1592053A (en) | Oxytetracycline compositions | |
MXPA00010224A (en) | Stable mitoxantron solutions | |
JP2770571B2 (ja) | 安定化された注射剤および注射剤の安定化法 | |
JP7178512B2 (ja) | 注入器用アドレナリン薬液 | |
KR100671449B1 (ko) | 송아지의 제단백 혈액 추출물을 함유하는 점안용 액제조성물 | |
KR930001302B1 (ko) | 시플로플록사신의 주사용 조성물 및 그 제조방법 | |
JP3208166B2 (ja) | アミノ酸含有輸液の安定化方法 | |
US5834520A (en) | Container for injectable mesna solutions | |
JP2000212086A (ja) | ノルフロキサシン点眼薬液 | |
ZA200504437B (en) | Ifosamide composition for parenteral administration and a process for their preparation | |
JP2008094779A (ja) | 眼科用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |